KALARIS THERAPEUTICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
KALARIS THERAPEUTICS, INC. (KLRS) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.53 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-17
- KALARIS THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- KALARIS THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00.
- KALARIS THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $23.30M.
- KALARIS THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-06-30 was -$10.00K.
- KALARIS THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $1.53M.
- KALARIS THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $14.72M, a 44.22% decline from fiscal 2021.
- KALARIS THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $26.39M.
- KALARIS THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $13.21M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.53M 10-K · filed 2026-03-17 | ||
| 2025-09-30 | $1.53M 10-Q · filed 2025-11-12 | |||
| 2022-12-31 | $14.72M 10-K · filed 2024-03-15 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $23.30M derived: sum of 2 quarters · filed 2023-02-15 | $23.29M derived: sum of 3 quarters · filed 2023-02-15 | $26.39M 10-K · filed 2023-02-15 |
| 2021-09-30 | $23.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $23.29M derived: sum of 2 quarters · filed 2022-11-03 | $26.39M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $3.09M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $3.10M 10-Q · filed 2022-05-05 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $6.32M derived: sum of 2 quarters · filed 2021-02-12 | $13.21M 10-K · filed 2021-02-12 | |
| 2019-09-30 | $6.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $13.21M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $6.89M 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |